Sensus Healthcare (NASDAQ:SRTS) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Sensus Healthcare, Inc. (NASDAQ:SRTS) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $6.85 and traded as low as $5.36. Sensus Healthcare shares last traded at $5.38, with a volume of 280,695 shares changing hands.

Analysts Set New Price Targets

SRTS has been the topic of several research reports. Maxim Group raised their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Lake Street Capital started coverage on Sensus Healthcare in a report on Friday, January 31st. They issued a “buy” rating and a $18.00 target price for the company. Finally, HC Wainwright upped their price target on Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, February 10th.

Sensus Healthcare Stock Down 3.2 %

The firm has a market capitalization of $88.18 million, a price-to-earnings ratio of 13.45 and a beta of 1.24. The stock has a 50 day moving average of $6.85 and a 200 day moving average of $6.84.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. Analysts predict that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Sensus Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC increased its stake in shares of Sensus Healthcare by 175.5% during the fourth quarter. Squarepoint Ops LLC now owns 85,677 shares of the company’s stock valued at $593,000 after acquiring an additional 54,576 shares during the period. Man Group plc lifted its holdings in shares of Sensus Healthcare by 34.0% in the fourth quarter. Man Group plc now owns 59,338 shares of the company’s stock valued at $411,000 after buying an additional 15,059 shares during the period. OMERS ADMINISTRATION Corp bought a new position in Sensus Healthcare during the fourth quarter valued at about $381,000. Millennium Management LLC grew its holdings in Sensus Healthcare by 256.6% during the fourth quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock worth $590,000 after acquiring an additional 61,403 shares during the period. Finally, BNP Paribas Financial Markets bought a new stake in Sensus Healthcare in the fourth quarter worth about $47,000. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.